Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESLIM-01: HMPL-523 in Primary Immune Thrombocytopenia
NCT05029635Phase 3Completed
- Sponsor
- HUTCHMED
- Start
- Oct 2021
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sovleplenib in primary immune thrombocytopenia (ITP), sponsored by HUTCHMED. Started Oct 2021; status: completed.
02
Drugs
sovleplenib
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05029635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05029635.